mining melanoma with microarrays

Speakers 21 Jeffrey M. Trent, Ph.D. Cancer Genetics Branch National Human Genome Research Institute 49 Convent Drive, MSC 4470 Building 49, Room 4A22 Bethesda, Maryland 20892-4470 USA Jeffrey M. Trent, Ph.D., is Scientific Director of the National Human Genome Research Institute (NHGRI), and also serves as Chief of NHGRI’s Cancer Genetics Branch. He is also an Adjunct Professor of Oncology at the Johns Hopkins University. He spe- cializes in studying the molecular changes related to the predis- position and progression of cancer. After earning his undergrad- uate degree from Indiana University, Dr. Trent received M.S. and Ph.D. degrees in genetics from the University of Arizona. Prior to his arrival at the NIH, Dr. Trent was the Emanuel N. Maisel Professor of Oncology and Professor of Radiation Oncology and Human Genetics at the University of Michigan, Ann Arbor. He also served as Director of the Division of Cancer Biology, and Director of Basic Sciences in the University of Michigan’s Comprehensive Cancer Center. In 1993, Dr. Trent came to the National Human Genome Research Institute to establish and direct its Division of Intramural Research. Under his guidance, the division has become a major research center in human genetics. Mining melanoma with microarrays The development and progression of cancer is accompanied by complex changes in patterns of gene expression. In the USA, malignant neo- plasms of the skin are the most common cancers of humankind. Incidence rates of melanoma have risen especially steeply since the mid- 1970s with an almost complete absence of significant advances in non- surgical treatment of advanced malignant melanoma over this time peri- od. Efforts to reduce mortality must rely on earlier diagnosis, but also on understanding the biology and genetics of this difficult disease. We have used high-density microarrays to search for differences in gene expression profiles associated with melanoma. Applications of multiple data analysis and integration methods including multidimensional scaling to represent the relationships among cell lines and tumor biopsies will be presented in order to document a consistent pattern of gene expression characterizing a subset of these cancers. This information will be related to clinical and known biologic information. These data are providing the leads for further investigation of the genetic basis of the tumorigenic phenotype of melanocytic lesions. © 1999 Nature America Inc. • http://genetics.nature.com © 1999 Nature America Inc. • http://genetics.nature.com

Upload: jeffrey-m

Post on 21-Jul-2016

212 views

Category:

Documents

0 download

Report

Download

Embed Size (px):

TRANSCRIPT

Page 1: Mining melanoma with microarrays

Speakers

Jeffrey M. Trent, Ph.D.

Cancer Genetics BranchNational Human Genome Research Institute49 Convent Drive, MSC 4470Building 49, Room 4A22Bethesda, Maryland 20892-4470USA

Jeffrey M. Trent, Ph.D., is Scientific Director of the NationalHuman Genome Research Institute (NHGRI), and also serves asChief of NHGRI’s Cancer Genetics Branch. He is also an AdjunctProfessor of Oncology at the Johns Hopkins University. He spe-cializes in studying the molecular changes related to the predis-position and progression of cancer. After earning his undergrad-uate degree from Indiana University, Dr. Trent received M.S. andPh.D. degrees in genetics from the University of Arizona. Priorto his arrival at the NIH, Dr. Trent was the Emanuel N. MaiselProfessor of Oncology and Professor of Radiation Oncology andHuman Genetics at the University of Michigan, Ann Arbor. Healso served as Director of the Division of Cancer Biology, andDirector of Basic Sciences in the University of Michigan’sComprehensive Cancer Center. In 1993, Dr. Trent came to theNational Human Genome Research Institute to establish anddirect its Division of Intramural Research. Under his guidance,the division has become a major research center in humangenetics.

Mining melanoma with microarrays

The development and progression of cancer is accompanied by complexchanges in patterns of gene expression. In the USA, malignant neo-plasms of the skin are the most common cancers of humankind.Incidence rates of melanoma have risen especially steeply since the mid-1970s with an almost complete absence of significant advances in non-surgical treatment of advanced malignant melanoma over this time peri-od. Efforts to reduce mortality must rely on earlier diagnosis, but also onunderstanding the biology and genetics of this difficult disease. We haveused high-density microarrays to search for differences in gene expres-sion profiles associated with melanoma. Applications of multiple dataanalysis and integration methods including multidimensional scaling torepresent the relationships among cell lines and tumor biopsies will bepresented in order to document a consistent pattern of gene expressioncharacterizing a subset of these cancers. This information will be relat-ed to clinical and known biologic information. These data are providingthe leads for further investigation of the genetic basis of the tumorigenicphenotype of melanocytic lesions.

199

9 N

atu

re A

mer

ica

Inc.

• h

ttp

://g

enet

ics.